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Abstract 
 
Ascidians are well known to accumulate extremely high levels of vanadium in their blood cells. 
Several key proteins related to vanadium accumulation and physiological function have been isolated 
from vanadium-rich ascidians. Of these, vanadium(IV)-binding protein-129 (VBP-129) is a unique 
protein that has been identified from the blood plasma of an ascidian Ascidia sydneiensis samea, but 
its metal binding domains are not known. In this study, several deletion and point mutants of VBP-129 
were generated, and their metal binding abilities were assessed by immobilized metal ion affinity 
chromatography (IMAC) and electron spin resonance spectroscopy (ESR). The internal partial protein, 
VBP-Int41, did not bind to VIV, but the two constructs, VBP-N52 and VBP-Int55, added with 
additional 11 or 14 neighboring amino acids bound to VIV. Mutations for cysteine-47 and lysine-50 in 
VBP-Int55 diminished VIV-binding in VBP-Int55, suggesting that these amino acid residues play 
important roles in binding VIV. ESR titration analysis revealed that VBP-129, VBP-N52 and 
VBP-Int55 could bind to 6, 3 and 2 VIV ions, respectively. ESR spectrum analysis indicated a N2O2 
coordination geometry, which is similar to Vanabins. The cysteines may contribute to the maintenance 
of the three-dimensional structure that is necessary for binding VIV ions. VBP-129 did not have a 
VV-reductase activity, as expected from its tissue localization in blood plasma. This study provided the 
evidences that VBP-129 possesses VIV-binding domains that make a similar coordination to VIV as 
those by Vanabins but VBP-129 acts solely as VIV-chaperon in blood plasma. 
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1. Introduction 
 
     The unusual ability of ascidians to accumulate high levels of vanadium ions has been attracting 
attention in biological and chemical disciplines for a century [1]. Vanadium ions are stored in the 
vacuoles of vanadium-containing cells called vanadocytes, where high levels of protons and sulfate 
ions are also found. The maximum concentration of vanadium can reach 350 mM in vanadocytes of 
Ascidia gemmata, belonging to the class Ascidiidae, and is thought to be the highest metal 
accumulation factor of any living organism (107 times against its concentration in natural sea water, 35 
nM). Vanadium is usually found in the +5 oxidation state (HVO42- or H2VO4-; VV) in the natural 
aquatic environment, but most of these ions are reduced to +3 (V3+; VIII) via the +4 state (VO2+; VIV) 
during assimilation [2, 3]. Additionally, most vanadium ions are stored in the vacuoles of signet ring 
cells, a type of blood cell, and are often referred to as vanadocytes [4, 5]. 
     Ongoing research over the last two decades has identified many proteins involved in the process 
of accumulating and reducing vanadium in vanadocytes, blood plasma, and the digestive tract of 
ascidians, such as vacuolar-type H+-ATPase [6-8], the chloride channel [9], the sulfate transporter [10], 
enzymes of the pentose-phosphate pathway [11-14], the glutathione transferase [15], Vanabins [16-18], 
and a vanadium transporter [19]. 
     Two types of vanadium-binding proteins that are expressed in blood plasma have been identified 
in A. sydneiensis samea. One protein was identified as a member of the Vanabin family, VanabinP, and 
its recombinant form binds a maximum of 13 VIV ions per molecule with a Kd of 2.8×10-5 M [18]. The 
other protein was named VBP-129; it binds to VIV ions as well as to FeIII, CoII, CuII, and ZnII ions [20]. 
A truncated form of VBP-129 that does not bind to VIV was also discovered, which has been called 
VBP-88 for its lack of 41 amino acid residues [20]. But, the properties such as binding number and 
coordination geometry in VBP-129 have not been revealed. 
     In this study, we sought to reveal the position and property of VIV-binding domain(s) of 
VBP-129 as well as the contribution of crucial amino acids for the binding of VIV. According to the 
differential sequence between full-length VBP-129 and its spontaneous truncated form VBP-88, 
several deletion and point mutants of VBP-129 were created using PCR amplification and in vitro 
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site-directed mutagenesis. Their metal binding abilities were assessed by IMAC and ESR. ESR 
measurements were conducted to reveal binding number and coordination geometry of VIV to 
VBP-129. Since reductase activity was not detected, VBP-129 seemed to act solely as a VIV-carrier 
protein in blood plasma. 
 
2. Material and methods 
 
2.1 Construction of expression plasmids 
 
     Deletion mutants of VBP-129 were constructed by PCR amplification using a VBP-129 
expression plasmid [20] as the template. Primer sets and templates used are listed in Table 1. PCR 
reactions consisted of 100 ng plasmid DNA, 200 pmol of each primer, each dNTP at 0.2 mM, 1× 
reaction buffer, and 2.5 units of Taq DNA polymerase (TaKaRa, Inc.) in a total volume of 50 µL. 
Amplification was performed with an initial denaturation at 94°C for 2 min, 30 cycles of 94°C for 30 s, 
55°C for 30 s, and 72°C for 30 s, and a final extension at 72°C for 5 min. After purification by agarose 
gel electrophoresis and cloning into pBluescript/EcoRV/dT vector, the nucleotide sequence was 
confirmed using an ABI 3130 automated DNA sequencer (Applied Biosystems Japan Ltd.) at the 
Natural Science Center for Basic Research and Development, Hiroshima University (N-BARD). 
    Each plasmid DNA was digested with restriction enzymes to excise the amplified fragments. 
These fragments were ligated into the multiple cloning sites of the expression vector pMAL-c2X 
(New England BioLabs), which contains the lac promoter and a coding region for MBP. Each plasmid 
was introduced into Escherichia coli BL21 for protein expression. 
     Plasmid vector and host E. coli strain for expressing another vanadium-binding protein, 
Vanabin1, were the same ones as used in our previous work [16]. 
 
2.2 In vitro site-directed mutagenesis 
 
     Site-directed mutagenesis of the coding region of VBP-129 and VBP-Int55 was conducted by a 
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PCR-based in vitro procedure based on the manufacturer’s protocol as described previously [21], 
using the plasmid vectors pMal-p2X with the VBP-129 insert and pMal-c2X with the VBP-Int55 
insert as templates. The combination of primer sets and template DNAs are listed in Table 1. Target 
residues were cysteine-47 (TGC) and lysine-50 (AAA) in the VBP-Int55 amino acid sequence, and 
cysteine-80 (TGC) and lysine-83 (AAA) in the VBP-129 amino acid sequence (Fig. 1). The cysteine 
and lysine were substituted by serine (AGC) and alanine (GCA), respectively. Each primer pair had a 
mutagenizing codon, which was flanked by complementary regions of 9-12 nucleotides. 
     The PCR reaction mix contained 50 ng of plasmid DNA, 35 pmol of each mutagenizing primer, 
1× Pfu reaction buffer (Stratagene), 0.2 mM of each dNTP, and 2.5 units of Pfu turbo DNA 
polymerase (Stratagene) in a total volume of 50 µL. After incubation at 95°C for 30 s, 12 cycles of 
30 s at 95°C, 60 s at 55°C, and 14 min at 68°C were conducted. After chilling on ice for 2 min, the 
restriction enzyme DpnI (20 units) was added and the reaction was incubated at 37°C for 60 min. An 
aliquot (1 µL) was used to transform competent E. coli DH5α cells. Following selection on plates 
LB-Amp medium with ampicillin, nucleotide sequences were determined as mentioned above. Each 
plasmid was introduced into E. coli BL21 for protein expression. 
 
2.3 Recombinant protein expression 
 
     Recombinant proteins were prepared as described previously [20]. Briefly, E. coli cells 
transformed with each plasmid DNA were incubated overnight at 37°C in 200-mL LB-Amp medium 
containing ampicillin (50 µg/mL). After dilution with 1,800-mL fresh LB-Amp medium, 0.1 mM 
IPTG was added and the culture was incubated at 37°C for 6 h. The fusion protein was purified by 
amylose resin column chromatography and digested with 1:500 (w/w) of factor Xa (Haematologic 
Technologies Inc.) at 4°C for 18 h. The excised protein was then purified by DEAE Sephacel anion 
exchange chromatography (GE Healthcare Bioscience Japan). Trace metal ions were removed by 
dialysis against approximately 100 volumes of Tris-EDTA solution (100 mM NaCl, 25 mM Tris-HCl, 
50 mM EDTA, pH 7.5). EDTA was removed by dialysis three times against approximately 100 
volumes of binding buffer for each assay. The protein concentration was measured with the BioRad 
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protein assay kit (Bio-Rad Laboratories, Inc.) using BSA as a standard. 
 
2.4 Immobilized metal ion affinity chromatography (IMAC) 
 
     All buffers were prepared from DW and ultrapure-grade reagents, and degassed for 10 min 
under vacuum before use. Calcium chloride (CaII; CaCl2･2 H2O), cobalt sulfate (CoII; CoSO4･7 H2O), 
copper chloride (CuII; CuCl2･2 H2O), iron chloride (FeIII; FeCl3), magnesium chloride (MgII; MgCl2･6 
H2O), manganese chloride (MnII; MnCl2), vanadyl sulfate (VIV; VOSO4.n H2O, n = 3-4), and zinc 
chloride (ZnII; ZnCl2) were used as 99.9% pure reagents purchased from Wako Pure Chemicals, Japan. 
All these metal compounds were dissolved in DW at 0.1 M. Given that FeIII and ZnII solutions contain 
precipitates, only supernatants were used after settling the solutions for several minutes. Hence the 
concentration of FeIII and ZnII are slightly lower then the initial concentration of 0.1M, but they were 
enough to charge the chelating resin. Chelating Sepharose FF resin (GE Healthcare Bioscience Japan) 
was washed three times with water and mixed with each metal solution in a 2.0-mL plastic tube for 
15 min (125 µL bed volume per each tube). The resin was washed three times with DW and twice with 
binding buffer (100 mM NaCl, 20 mM Na3PO4, pH 7.2). The protein in the binding buffer 
(~300 µg/mL, 500 µL) was mixed with the resin by rotation for 30 min at 4°C. Non-bound proteins 
were removed by centrifugation and the resin was washed three times with binding buffer. Bound 
proteins and metal ions were eluted with elution buffer (100 mM NaCl, 20 mM Na3PO4, 50 mM 
EDTA, pH 8.0, 400 µL). Non-bound and bound protein fractions were analyzed by SDS-PAGE and 
CBB staining. 
 
2.5 ESR measurements 
 
     ESR measurements on Vanabin1 were done according to our previous study [22], while 
measurements on VBP-129 and its derivatives were done by a slightly modified protocol as described 
below. 
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     In the binding assay on VBP-129, proteins were dialyzed against a buffer (100 mM NaCl, 10 
mM Tris-HCl, pH 7.5; here we term it as a buffer A). Vanadyl sulfate (VIV; VOSO4·n H2O, n = 3-4) 
was dissolved in DW at 1 mM immediately prior to use. After mixing the proteins with the appropriate 
amount of 10×concentrated stock of the buffer A, the vanadium solution was added and the mixture 
was incubated for 5 – 10 min at room temperature. Longer incubation up to 3 h did not gave any 
significant changes in ESR spectrum. The mixture was placed in a quartz tube (5 × 100 mm, ST-X-5, 
Agri Co.) and frozen immediately in liquid nitrogen. ESR signals were recorded using the 
ELEXSYS-II E500 CW-ESR (Bruker BioSpin) with ER 4112V temperature control system at the 
N-BARD. The sample was inserted into the quartz dewar, which was held in a steam of temperature 
controlled nitrogen gas. ESR measurements were done at 78 – 80 K with a frequency of 9.4 GHz and a 
modulation (100 kHz) of 1 mT. Modulation amplitude was 10G, and receiver gain was 60 dB. 
Conversion time was 15ms. Microwave attenuation was 25 dB, and microwave power was 0.6325W. 
Number of scan was 3 times. There have been no significant differences among spectra recorded 
between 78 and 80 K. ESR parameters (A||, g||) were obtained from the spectrum. 
     In the reduction assay on VBP-129, sodium orthovanadate (99.98% Na3VO4, Sigma Aldrich) 
was dissolved in DW at 10 mM. The yellowish solution was incubated at 60°C until it became 
colorless. The protein solution was mixed with vanadate solution and the appropriate amount of 
10×concentrated stock of the buffer A to give the same buffer composition as the buffer A (100 mM 
NaCl, 10 mM Tris-HCl, pH 7.5). The mixed solution was incubated at 20°C for 8 h. The solution was 
then frozen in liquid nitrogen and ESR signals were recorded as described above.  
 
2.6 Determining VIV-binding parameters from ESR intensities 
 
     For determining the binding number and dissociation constant for VIV and a protein, relative 
ESR intensity for a specific resonance was integrated from each ESR spectrum. Assumed that a 
protein possesses multiple VIV-binding sites (n), a portion of the sites (q) were occupied by the metal 
ions by equilibrium. Using the total concentrations of vanadium (v) and protein (p), the dissociation 
constant (Kd) can be calculated with the following equation: 
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     At physiological pH and in the absence of coordinating ligands, free VIV is ESR-silent due to the 
formation of vanadyl hydroxides with various stoichiometries [25]. As shown in Fig. 4A, 
non-protein-bound VIV ions give little signal at the position of 3/2┴ peak. Therefore, we chose this 
peak for intensity analysis. Assuming free vanadium ions were in excess and signals from 
non-protein-bound VIV ions can be neglected at this pH [25], ESR signal at 3/2┴ is mostly derived from 
the occupied sites (q). Therefore, ESR intensity (I) can be approximated to be proportional to q: 
 
     In this equation, c is a coefficient to normalize the ESR intensity. By varying v and p, 
experimental data were obtained for I. Then, the best-fitting parameters, c, n and Kd, were calculated 
by repeating Monte Calro algorithm using the Pro Fit software running on a Macintosh OSX 
(QuantumSoft, Switherland). 
 
3. Results 
 
3.1 Metal-binding ability of VBP-Int41, VBP-N52 and VBP-Int55 
 
     In the previous study, a truncated form of VBP-129 that does not bind to VIV was discovered. It 
has been called VBP-88 for its lack of internal 41 amino acid residues [20]. We thought it should be a 
starting point to reveal VIV-binding domain(s) in VBP-129. In this study, a recombinant protein with 
the internal 41-amino-acid sequence between VBP-129 and VBP-88 was first constructed (VBP-Int41; 
Fig. 1). VBP-Int41 was applied to IMAC chelated with CaII, CoII, CuII, FeIII, MgII, MnII, VIV, or ZnII 
ions. Proteins bound with each immobilized metal ion were recovered and analyzed by SDS-PAGE. 
As a result, VBP-Int41 was found to bind with CoII, CuII, FeIII, MnII, and ZnII, but not with VIV ions 
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(Fig. 2). This result suggested that the internal sequence, VBP-Int41, was insufficient for binding of 
VIV ions. 
     Given that VBP-Int41 did not bind to VIV, we hypothesized that neighboring amino acids were 
necessary for its binding. To test this, we constructed VBP-N52 and VBP-Int55 recombinant proteins 
by adding neighboring amino acids to VBP-Int41 (Fig. 1). VBP-N52 extends up to the N-terminus of 
mature VBP-129 by adding 11 amino acid residues. The VBP-Int55 sequence included 14 amino acids 
that cover the putative α-helical region. Both proteins were applied to IMAC and were found to have 
an ability to bind VIV as well as to CoII, CuII, FeIII, MnII, and ZnII ions (Fig. 2). This data suggested that 
52 or 55 amino acid regions are sufficient for VIV-binding. 
 
3.2 Metal-binding abilities of VBP-Int55 and VBP-129 with point mutations 
 
     We hypothesized that the 14 amino acids form an important domain for VIV-binding in 
VBP-Int55 because the additional sequence included lysines and cysteines, which have been shown to 
be responsible for maintaining the structure and function of another vanadium-binding protein 
Vanabin2 [21-23]. Thus, we next created two mutants of VBP-Int55 with mutated residues at 
cysteine-47 and lysine-50, substituting them with serine (VBP-Int55 (C47S)) and alanine (VBP-Int55 
(K50A)), respectively. IMAC results indicated that VBP-Int55 (C47S) bound to CoII, CuII, FeIII, MnII, 
and ZnII ions but lost the VIV-binding ability (Fig. 3). VBP-Int55 (C47S) also lost their VIV-binding 
ability. This suggested that both cysteine-47 and lysine-50 in VBP-Int55 play an important role in 
binding VIV ions. 
     To test whether these two amino acid residues were responsible for VIV-binding in the 
full-length VBP-129, we created the mutants VBP-129(C80S) and VBP-129(K83A). VBP-129(K83A) 
bound to VIV in addition to CoII, CuII, FeIII, MnII, and ZnII ions (Fig. 3). This spectrum of selectivity 
was similar to the original VBP-129. Thus, the mutation in lysine-83 did not affect the overall ability 
of VBP-129 to bind VIV ions and its binding differed from VBP-Int55(K50A). On the other hand, 
VBP-129(C80S) retained its ability to bind to CoII, CuII, FeIII, MnII, and ZnII, but VIV-binding was very 
weak (Fig. 3). This suggested that the mutated cysteine-80 affected the overall ability of VBP-129 to 
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bind VIV ions. 
 
3.3 ESR measurement of VIV-binding in VBP-129 and its deletion mutants 
 
     ESR measurements were performed to determine binding number and dissociation constants 
between VBP-129 and VIV ions. A constant concentration (14 µM) of VBP-129 was mixed with 0–150 
µM VIV in a buffer containing 100mM NaCl and 10 mM Tris-HCl, pH 7.5. Results showed that the 
complex VIV–VBP-129 invariably exhibited a normal mononuclear-type VIV signal (Fig. 4). At 
physiological pH and in the absence of coordinating ligands, free VIV is ESR-silent due to the 
formation of vanadyl hydroxides with various stoichiometries [25], and the ESR signals are from 
protein-bound VIV. The protein-only sample showed a very weak signal due to crystal imperfections of 
quartz of the temperature regulating equipment, and the intensity of which was subtracted before 
calculating the intensity. The curve fitting data indicated that VBP-129 can bind up to 5.6 vanadium 
per protein with a dissociation constant of 3.8 × 10-6 M (Fig. 5A, Table 2). The ESR parameters of 
VIV–VBP-129 were g|| = 1.952 and A|| = 168.3×10-4 cm-1 (Table 3), at the boundary region of the N2O2 
and O2O2- equatorial donor sets in the g||-A|| diagram [24] . If we assume that lysine(s) contribute as a 
binding site and A|| is a sum of four equatorial donor sets including amino acid side chains 
(R-NH2 = 40.1×10-4 cm-1, R-COO- = 42.7×10-4 cm-1) and water molecule (H2O = 45.7×10-4 cm-1) [25, 
26], a combination of R-NH2:R-COO-:H2O=2:1:1 (sum = 168.6×10-4 cm-1) was closest to the 
measured A|| value. It is possible that histidine(s) and tyrosine(s) could contribute as binding site(s), 
but the number of these amino acids in VBP-129 are not enough to make a binding model that could 
explain a uniform increase of ESR intensity without changing A||. But still, it is possible that histidine 
can contribute some of the binding sites because the contribution of imidazole nitrogen of a histidine 
to A|| is similar to that of a lysine [26]. 
     We have also performed the same ESR analysis on the two deletion mutants, VBP-N52 and 
VBP-Int55 (Fig. 5B and 5C). Here we also describe the ESR data for another vanadium-binding 
protein Vanabin1 isolated from the same ascidian species (Fig. 5D) [16]. The results were summarized 
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in Tables 2 and 3. The coordination geometry of VIV in both proteins were similar to original VBP-129. 
It is also similar to that of Vanabin1 as determined here, and that of Vanabin2 [22]. 
 
3.4 Reduction of VV by VBP-129 
 
     Recently, our group reported that Vanabin2 can act as a VV-reductase in a thiol-disulfide 
exchange reaction cascade that included GSH and NADPH [27]. To examine the possibility that such a 
reduction can occur in blood plasma, we performed ESR analysis to examine VV-reductase activity of 
VBP-129 as described previously. The reaction cascade in this analysis corresponded to the right half 
of the cascade (Fig. 4 in ref. 27) starting from reduced GSH through the reduction of VV. 
     When orthovanadate was incubated with glutathione at 20°C for 8 h, we observed some signals 
which is different from that of VIV (Fig. 6B, D). We could not attribute the signals to any components. 
The mixture composition (Fig. 6B) was essentially same as that in our previous work (Fig. 3A 
spectrum2 in ref. 27) but the signals were very different. Incubation time, buffer composition and 
measurement temperature were different from each other. Some contaminating materials may affect 
the spectrum.  
     When 10 µM of VBP-129 was included in each reaction, the resulting peaks were not 
significantly different from those without VBP-129 (Fig. 6A, C). The mixture composition was same 
as that in our previous study (Fig. 3A spectrum 3 in ref. 27) (10 µM Vanabin2 in previous study vs. 10 
µM VBP-129 in this work). These results indicated that VBP-129 did not act as a VV-reductase under 
these experimental conditions. 
 
4. Discussion 
 
     Most of the vanadium ions accumulated in ascidians are ultimately localized in the vacuoles of 
vanadocytes [5]. However, the mechanism by which these ions are taken in before entry into these 
cells has not been completely determined. Vanadium-binding proteins found in the digestive system, 
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AsGST [15, 28], and those in blood plasma, VanabinP and VBP-129 [18, 20], presumably play 
important roles in the accumulation process. The present study focused on the vanadium-binding 
protein in blood plasma (VBP-129) and its truncated form (VBP-88), which were suitable starting 
points to identify VIV-binding domains, based on the affinity for VIV ions in the former, but the lack of 
binding in the latter [20]. In this study, we constructed several deletion and point mutants of VBP-129, 
examined the VIV-binding properties of them, and found that VBP-129 binds up to 6 VIV ions in the 
N2O2 coordination geometry. We also found that VBP-129 does not act as VV-reductase. 
     The 41-amino-acid region found in VBP-129, but not in VBP-88, was named VBP-Int41 
(Fig. 1). As shown in Figure 2, VBP-Int41 could not bind VIV, but did bind CoII, CuII, FeIII, MnII, and 
ZnII. In contrast, VBP-Int55 could bind VIV as well as the other five metal ions. VBP-N52 also showed 
similar properties to VBP-Int55 (Fig. 2). Specifically, VBP-Int41 was incapable of binding to VIV 
without the flanking amino acid residues. 
     The ESR results in this study revealed the coordination geometry of VIV in VBP-N52 and 
VBP-Int55 as well as VBP-129 as the N2O2 equatorial donor sets (Table 3). The coordination 
geometries of VIV in VBP-129, VBP-N52 and VBP-Int55 were very close to that found in the 
vanadium-binding protein Vanabin2, whose parameters were g|| = 1.943 and A|| = 168.7 × 10-4 cm-1 
[22]. Also, we revealed in this study that those parameters of Vanabin1 were very close to these values. 
Thus, this type of coordination, a possible combination of ligands of R-NH2:R-COO-:H2O=2:1:1 (calc. 
sum = 168.6×10-4 cm-1), is common to vanadium-binding proteins in ascidians. It should be noted that 
the additivity of A|| is not unique and further studies should be used to confirm the assignments. 
    ESR spectrometry has been extensively used to determine the coordination environment around 
VIV in several vanadium-binding proteins identified from other animals. Table 3 summarizes the axial 
parameter data on the proteins whose X-band ESR parameters are obtained in a frozen aqueous 
solution [22, 29-31]. The parameters for VBP-129 are close to those of other vanadium-binding 
proteins, Vanabin1 and Vanabin2 [22], found in the same species of ascidian. They are also close to A 
site of human transferrin [29, 32, 33]. Although the coordination geometry for FeIII in this site has been 
revealed to be Tyr:His:Asp:hydrogencarbonate=2:1:1:1 by X-ray crystalography [34, 35] and the site 
is common to VIV and FeIII [33], it is still not clear whether same set of amino acid residues bind to 
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both VIV and FeIII at this site. 
     In vitro mutagenesis study suggested that lysine-50 in VBP-Int55 plays an important role in 
binding VIV ions. Because the mutation in lysine-50 diminished VIV-binding and ESR titration 
revealed that the maximum binding number for VIV is two per molecule of VBP-Int55, the lysine-50 in 
VBP-Int55 could make a site for binding two VIV ions. Another possibility is that lysine-50 makes a 
site for a single VIV ion and the mutation also affect the putative secondary site. The latter is more 
probable because there have been no report for the coordination of two VIV ions per one lysine side 
chain. The corresponding mutation in VBP-129 (K83A) did not diminish binding to VIV. Based on the 
ESR results that VBP-129 could bind to six VIV ions, it is possible that lysine-50 contributed only to 
the binding sites for two of VIV ions and remaining ions bound to site(s) that are only formed in the 
full-length VBP-129, but not in VBP-88 or VBP-Int55. Another deletion mutant, VBP-N52, was 
revealed to bind up to three VIV ions in relatively high affinity. It is important to further analyze the 
role of each amino acid, especially glutamate and aspartate, in the N-terminal stretch in binding 
activity. A possible binding model is given in Fig. 7. In this model, we assumed that a single molecule 
of VBP-129 could bind to 6 VIV ions. Cross binding between two or more molecules of VBP-129 
could be possible. We have found in our previous study that recombinant VBP-129 could polymerize 
[20], but the relationship between polymerization and metal-binding is not clear. 
     Cysteines are involved in the maintenance of structure and VV-reduction in Vanabin2, which 
contains 18 cysteines. In this study, mutagenesis studies suggested that cysteine-47 in VBP-Int55 
(cysteine-80 in VBP-129) plays an important role in binding VIV (Fig. 3) and VBP-129 did not act as a 
VV-reductase (Fig. 6). According to ESR parameter analysis (Table 3), the role of this cysteine residue 
is not as a VIV-binding site. Thus, the cysteines may contribute to the maintenance of the 
three-dimensional structure that is necessary for binding VIV ions. Future studies are recommended to 
determine the status of disulfide bridges in VBP-129. 
     VBP-129 can interact with VanabinP, which can bind both VIV and VV ions [18]. VBP-129 and 
VanabinP form a stable complex, regardless of metal conditions [20]. Although transfer of vanadium 
ions between VBP-129 and VanabinP has not been determined, these two proteins may act together to 
deliver VIV ions. VV reduction by VanabinP and subsequent cooperative transport of VIV by a 
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VanabinP–VBP-129 complex could occur and to be determined in future studies. 
     Identifying the domain responsible for protein-protein interaction with VanabinP is also needed 
to further understand the transport mechanism. We were unable to develop a model of the protein 
structure because no suitable base model was found for VBP-129. We are currently developing 
solutions to determining the three-dimensional structure experimentally by NMR, which will help us 
to better understand structure-function relationships. 
     Approaches such as deletion and point mutagenesis are frequently used to identify protein 
domains or regions responsible for specific function. In vitro point mutagenesis studies are too 
numerous to be fully elaborated. Studies on the function of N-terminal metal binding sites in P1B-type 
ATPases, such as Wilson and Menkes proteins in humans, are good examples of the use of deletion 
mutagenesis [36]. Copper binding sites in amyloid β protein were also extensively studied by a series 
of deletion mutants [37]. The domains for binding to DNA by nuclear proteins, protein-protein 
interaction, and secretion have also been studied using this technique [38-40]. These approaches are 
complementary to determining three-dimensional structure and help establishing structure-function 
relationships. 
     In summary, we revealed the VIV-binding domain and the VIV-binding capabilities of VBP-129 
as well as the contribution of crucial amino acids for the binding of VIV. We found that VBP-129 binds 
up to six VIV ions and the coordination geometry was N2O2 donor sets, possibly composed of a 
combination of ligands of R-NH2:R-COO-:H2O=2:1:1 (A|| calculated = 168.6×10-4 cm-1). Because we 
did not obtain any evidence of VV reduction by VBP-129, it was suggested that VBP-129 acts solely as 
a VIV-carrier in blood plasma that delivers VIV ions to target proteins in some tissue(s) or cell(s).  
 
Abbreviations 
BSA  bovine serum albumin 
CBB  coomassie brilliant blue 
CW-ESR  constant-wave electro spin resonance 
DEAE  diethylaminoethyl 
DW deionized pure water 
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EDTA  ethylenediaminetetraacetic acid 
ENDOR electron nuclear double resonance) 
ESR electron spin resonance 
ESEEM electron spin-echo envelope modulation 
IMAC  immobilized metal ion affinity chromatography 
IPTG  isopropyl-β-d-thiogalactopyranoside 
LB-Amp  Luria-Bertani broth supplemented with ampicillin 
MBP  maltose binding protein 
NMR  nuclear magnetic resonance 
PCR polymerase chain reaction 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Tris tris(hydroxymethyl)aminomethane 
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Table 1. List of primer sets and templates used for construction of VBP-129 mutants. 
Protein name Primers a) Templates b) 
VBP-Int41 5’-GGAATTCCTGTCCGATTGCATCC-3’ 
5’-GGAATTCCTGTCCGATTGCATCC-3’ 
pMAL-p2X:VBP-129 
VBP-N52 5’-GGATCCCTGGGAAGCGATGCT-3’ 
5’-CGTCGACTCATTTTAGGCGAAGT-3’ 
pMAL-p2X:VBP-129 
VBP-Int55 5’-GGAATTCCTGTCCGATTGCATCC-3’ 
5’- CGTCGACTCAAATTCTT TCGGTGT-3’ 
pMAL-p2X:VBP-129 
VBP-Int55(C47S) or 
VBP-129(C80S) 
5’-AATGCGCCAAAGCCTTAACAAAT-3’ 
5’-ATTTGTTAAGGCTTTGGCGCATT-3’ 
pMAL-c2X:VBP-Int55 or 
pMAL-p2X:VBP-129 
VBP-Int55(K50A) or 
VBP-129(K83A) 
5’-ATGCCTTAACGCATACACCGAAAG-3’ 
5’-CTTTCGGTGTATGCGTTAAGGCATT-3’ 
pMAL-c2X:VBP-Int55 or 
pMAL-p2X:VBP-129 
a) Primers for deletion mutants include artificial restriction sites (underlined). Primers for point 
mutants include mutagenizing codon in their central region (double-underlined). 
b) Template plasmid DNAs are derived from the previous study [20]. 
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Table 2. ESR titration for the VIV-binding to vanadium-binding proteins VBP-129, its deletion mutants 
and Vanabins. 
 Nmax Kd (M) reference 
VBP-129 5.6 3.8 × 10-6 this study 
VBP-N52 2.7 0.99 × 10-6 this study 
VBP-Int55 2.0 8.2 × 10-6 this study 
Vanabin1 15 < 0.1 × 10-6  this study 
Vanabin2 24 < 0.1 × 10-6  [22] 
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Table 3. ESR parameters for the VIV complexes formed by proteins. 
 g|| A|| (×10-4 cm-1) reference 
VBP-129 1.952 168.3 this study 
VBP-N52 1.947 167.4 this study 
VBP-Int55 1.954 168.9 this study 
Vanabin1 1.946 169.2 this study 
Vanabin2 1.943 168.7 [22] 
hTf, A site 1.937 168.3 [29] 
hTf, B1 site 1.941 170.5 [29] 
hTf, B2 site 1.935 171.8 [29] 
HSA, weak site 1.946 171.2 [29] 
HSA, strong site 1.947 164.6 [29] 
HSF 1.940 173.0 [30] 
IgG, site 1 1.960 158.8 [31] 
IgG, site 2 1.951 163.6 [31] 
IgG, site 3 1.947 167.4 [31] 
hTf: human transferrin, HSA, human serum albumin, HSF: horse spleen ferritin, IgG: 
Immunoglobulin G. 
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Figure legends 
 
 
Fig. 1. Amino acid sequences of VBP-129 and its deletion mutants. Lower-case characters indicate 
signal sequences. Mutated sites are boxed. Asterisks indicate putative helical domains. Lysines (K) are 
shown in blue, while aspartic acid and (D) and glutamic acids (E) are shown in red. 
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Fig. 2. IMAC analysis of metal binding by deletion mutants of VBP-129. The metal-binding 
experiment was performed using 100 mM NaCl and 20 mM Na3PO4 at pH 7.2. Recombinant proteins 
were applied to IMAC charged with metal ions indicated at the top or without any metal ions (–), 
respectively, and incubated for 30 min at 4°C. After removal of non-bound proteins, the metal-bound 
fraction was eluted with EDTA-containing buffer, as described in the Materials and Methods. Protein 
fractions were analyzed by SDS-PAGE and CBB staining. Arrowheads indicate the protein bands. 
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Fig. 3. IMAC analysis of metal binding by point mutants of VBP-Int55 and VBP-129. The 
metal-binding experiment was performed using 100 mM NaCl and 20 mM Na3PO4 at pH 7.2. 
Recombinant proteins were applied to IMAC charged with metal ions indicated at the top or without 
any metal ions (–), respectively, and were examined as in Fig. 2. Arrowheads indicate the protein 
bands. 
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Fig. 4. Representative CW ESR spectra of samples containing various ratios of VIV and VBP-129. (A) 
Spectra recorded from 2700 G to 3900 G. The arrow indicates the 51V hyperfine line (3/2⊥). VIV-only 
sample (10 µM VIV without protein) and protein-only sample (0 µM VIV, 14 µM VBP-129) are 
included as references. (B) Magnified overwrapped spectra for the 51V hyperfine line (3/2⊥) in (A). 
The intensity of protein-only sample (0 µM VIV) has been subtracted from each spectra. Conditions: T 
= 79 K; microwave frequency, 9.4 GHz; microwave power, 1 mW; modulation (100 kHz), 1 mT; 
Resolutions = 0.4 G per point. Final concentrations: [VIV] =0-150 μM , [VBP-129] = 14 μM, [Tris] = 
10 mM, and [NaCl] = 100 mM, pH 7.5, in a total volume of 100 μL.  
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Fig. 5. ESR spectrometric titration of VIV ion bound to (A) VBP-129, (B) VBP-N52, (C) VBP-Int55 
and (D) Vanbabin1. ESR intensities of the MI = 3/2⊥ lines for various VIV ions per protein ratios are 
plotted by black diamonds. Dotted lines indicates the best curve fittings whose parameters were 
summarized in Table 2. 
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Fig. 6. ESR spectrometric analysis of VV-reduction by VBP-129. Each component was mixed and 
incubated at 20°C for 8 h before ESR measurement at 80K. Spectrums: (A), 10 mM VV + 2 mM GSH 
+ 10 µM VBP-129; (B), 10 mM VV + 2 mM GSH; (C), 10 mM VV + 0.05 mM GSH + 10 µM 
VBP-129; (D), 10 mM VV + 0.05 mM GSH. Buffer composition was [Tris] = 10 mM, and [NaCl] = 
100 mM, pH 7.5. Conditions: T = 79 K; microwave frequency, 9.4 GHz; microwave power, 1 mW; 
modulation (100 kHz), 1 mT; Resolutions = 0.4 G per point. 
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Fig. 7. A possible model of the binding of VBP-129 to VIV. VBP-Int41 (pink) contains 8 lysines (K) 
and 4 aspartic acid/glutamic acid (D/E), but cannot bind VIV (V). By adding neighboring amino acid 
residues, VBP-N52 (blue+pink) and VBP-Int55 (pink+yellow) can bind three or two VIV in N2O2 
geometry, respectively, possibly composed of a combination of ligands of K:(D/E):H2O=2:1:1. The 
full-length VBP-129 can additionally bind another VIV by using additional sets of K or D/E in the 
C-terminal stretch. 
